Application of glipizide in preparing drugs for treating liver fibrosis

By inhibiting the expression of Collagen I and α-SMA, glipizine drugs significantly alleviate liver fibrosis, solve the problem of liver fibrosis treatment in the prior art, and provide a new therapeutic strategy to achieve liver fibrosis effective intervention.

CN115381842BActive Publication Date: 2024-11-26SCNU QINGYUAN INSTITUTE OF SCIENCE & TECHNOLOGY INNOVATION CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210954719.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-10
Publication Date
2024-11-26
Estimated Expiration
2042-08-10

AI Technical Summary

Technical Problem

The prior art is difficult to effectively block or slow down the progress of liver fibrosis, especially in terms of pathological angiogenesis and hepatic sinus capillaryization, and there is a lack of effective therapeutic strategies.

Method used

Using glipizine as the active ingredient, drugs for the treatment or adjuvant treatment of liver fibrosis are developed, including oral and injectable dosage forms, by inhibiting the expression of Collagen I and α-SMA, and effective doses are 4 mg/kg to 10 mg/kg. Combined with pharmaceutically acceptable excipients, different dosage forms such as tablets, capsules, liquid agents, etc. are prepared.

Benefits of technology

Glipizine significantly reduced the expression levels of Collagen I and α-SMA in liver tissues, alleviated CCl4-induced liver fibrosis in mice, and provided a novel drug development prospect for the treatment of liver fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0003790829380000011
    Figure HDA0003790829380000011
Patent Text Reader

Abstract

The present invention provides the use of glipizide in the preparation of a drug for treating liver fibrosis. The present invention proves that glipizide can reduce CCl 4 Induced liver fibrosis in mice, hematoxylin-eosin (HE), Sirius red staining, and immunohistochemical detection of the expression of Collagen Ⅰ and α-SMA were used to verify the therapeutic effect of glipizide on liver fibrosis. Glipizide can be used as a promising drug for the treatment of liver fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to the application of glipizide in preparing a drug for treating liver fibrosis. Background Art

[0002] Glipizide is a second-generation sulfonylurea oral hypoglycemic drug, which is mainly used in the treatment of type 2 diabetes. It mainly binds to the corresponding receptors on the pancreatic β cell membrane to shut down the ATP-dependent K + channels that allow Ca2+ to cross the cell membrane 2+ flow, causing intracellular Ca 2+ Increase, thereby promoting insulin secretion, increasing peripheral tissue sensitivity to insulin, reducing liver glucose output, significantly reducing fasting and postprandial blood sugar, and not increasing fasting insulin levels. It is widely used in clinical practice. Previous studies have shown that Glipizide inhibits endothelial cell proliferation and migration by upregulating the endogenous angiogenesis inhibitory gene natriuretic peptide receptor 1 (NPR1), reducing the formation of blood vessels in tumors, resulting in the inability of tumors to obtain sufficient nutrients, reducing tumor cell proliferation, and ultimately hindering tumor growth and metastasis. In addition, Glipizide can also inhibit tumor-induced angiogenesis by downregulating HMGIY / ANGPT1 signals. These indicate that Glipizide affects some diseases by inhibiting angiogenesis.

[0003] Liver fibrosis is a progression of chronic liver damage caused by a variety of factors, including viral hepatitis, alcoholic liver damage, non-alcoholic fatty liver disease, and autoimmune liver disease. Without effective intervention, advanced liver fibrosis may develop into irreversible cirrhosis, which is the leading cause of liver-related death worldwide. Recent studies have shown that pathological angiogenesis and hepatic sinusoidal capillarization are closely related to the progression of liver fibrosis. During liver fibrosis, a variety of pro-angiogenic factors are abnormally expressed, including vascular endothelial growth factors (VEGFs), hypoxia-inducible factors (HIFs), fibroblast growth factors (FGFs), angiopoietins (Angs), and platelet-derived growth factors (PDGFs). Therefore, anti-angiogenic therapy seems to provide a new therapeutic strategy to block or slow liver fibrosis. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the first aspect of the present invention proposes the use of glipizide in the preparation of a drug for inhibiting collagen I.

[0005] The second aspect of the present invention provides the use of glipizide in preparing a drug for inhibiting α-SMA.

[0006] The third aspect of the present invention provides the use of glipizide in the preparation of a drug for treating or assisting in the treatment of liver fibrosis.

[0007] According to a first aspect of the present invention, a use of glipizide in preparing a drug for inhibiting collagen I is proposed.

[0008] In some embodiments of the present invention, the medicament comprises glipizide as an active ingredient and a pharmaceutically acceptable excipient.

[0009] In some embodiments of the present invention, the effective dose of glipizide is 4 mg / kg to 10 mg / kg.

[0010] In some preferred embodiments of the present invention, the effective dose of glipizide is 5 mg / kg.

[0011] In some more preferred embodiments of the present invention, the medicament comprises glipizide as the sole active ingredient and pharmaceutically acceptable excipients.

[0012] In some more preferred embodiments of the present invention, the dosage form of the drug is an oral dosage form or an injection dosage form.

[0013] In some more preferred embodiments of the present invention, the oral dosage form is a tablet, a capsule, an oral liquid, a granule or a powder.

[0014] According to a second aspect of the present invention, a use of glipizide in preparing a drug for inhibiting α-SMA is proposed.

[0015] In some embodiments of the present invention, the medicament comprises glipizide as an active ingredient and a pharmaceutically acceptable excipient.

[0016] In some embodiments of the present invention, the effective dose of glipizide is 4 mg / kg to 10 mg / kg.

[0017] In some preferred embodiments of the present invention, the effective dose of glipizide is 5 mg / kg.

[0018] In some more preferred embodiments of the present invention, the medicament comprises glipizide as the sole active ingredient and pharmaceutically acceptable excipients.

[0019] In some more preferred embodiments of the present invention, the dosage form of the drug is an oral dosage form or an injection dosage form.

[0020] In some more preferred embodiments of the present invention, the oral dosage form is a tablet, a capsule, an oral liquid, a granule or a powder.

[0021] According to the third aspect of the present invention, a use of glipizide in preparing a drug for treating or assisting in treating liver fibrosis is proposed.

[0022] In some embodiments of the present invention, the glipizide reduces the expression level of Collagen I, and further, the expression level of Collagen I is the expression level of Collagen I in liver tissue.

[0023] In some embodiments of the present invention, the glipizide reduces the expression level of α-SMA, and further, the expression level of α-SMA is the expression level of α-SMA in liver tissue.

[0024] In the present invention, since activated stellate cell α-SMA and extracellular matrix promote the progression of liver fibrosis during the formation of liver fibrosis, the measurement of α-SMA and Collagen I expression levels in liver tissue can be used to evaluate the progression of liver fibrosis.

[0025] In some embodiments of the present invention, the liver fibrosis is associated with at least one of viral hepatitis, alcoholic liver damage, non-alcoholic fatty liver disease and autoimmune liver disease.

[0026] In some embodiments of the present invention, the medicament comprises glipizide as an active ingredient and a pharmaceutically acceptable excipient.

[0027] In some embodiments of the present invention, the effective dose of glipizide is 4 mg / kg to 10 mg / kg.

[0028] In some preferred embodiments of the present invention, the effective dose of glipizide is 5 mg / kg.

[0029] In some more preferred embodiments of the present invention, the dosage form of the drug is an oral dosage form or an injection dosage form.

[0030] In some more preferred embodiments of the present invention, the oral dosage form is a tablet, a capsule, an oral liquid, a granule or a powder.

[0031] It is understood that, for the convenience of medication, the active ingredient glipizide can be processed into a specific dosage form with any one or more pharmaceutically acceptable excipients. These excipients can be diluents (such as starch, pregelatinized starch, dextrin, sucrose, lactose, mannitol and microcrystalline cellulose, etc.), absorbents (such as calcium sulfate, calcium hydrogen phosphate, light magnesium oxide and calcium carbonate, etc.), wetting agents (such as water and ethanol, etc.), binders (such as hydroxypropyl methylcellulose, povidone, starch slurry and syrup, etc.), disintegrants (such as dry starch, sodium hydroxymethyl starch, low-substituted hydroxypropyl cellulose, effervescent disintegrants and cross-linked polyvinylpyrrolidone, etc.), lubricants (magnesium stearate, talc, hydrogenated vegetable oil, polyethylene glycol and micropowder silica gel, etc.), colorants (such as titanium dioxide, sunset yellow, methylene blue and medicinal iron oxide, etc.), coating materials (such as acrylic resin, hydroxypropyl methylcellulose and povidone, etc.), solvents (such as water for injection, ethanol, propylene glycol and glycerol, etc.), acid-base regulators (such as hydrochloric acid, lactic acid, sodium hydroxide, tartaric acid and sodium tartrate, etc.), antioxidants (such as sodium sulfite, sodium pyrosulfite and sodium thiosulfate, etc.), antibacterial agents (such as phenol, benzyl alcohol and thimerosal, etc.), and isotonic regulators (such as sodium chloride and glucose, etc.).

[0032] It is to be understood that the oral tablet examples described in the embodiments of the present invention include but are not limited to enteric-coated tablets, coated tablets, film-coated tablets, sugar-coated tablets, dispersible tablets, sucking tablets, chewable tablets, effervescent tablets, scratched tablets, sustained-release and controlled-release dosage forms, sustained-release tablets, sustained-release coated tablets, controlled-release tablets, orally disintegrating tablets, lozenges, oral patches, etc.

[0033] It is to be understood that the oral capsules described in the embodiments of the present invention include but are not limited to hard capsules, soft capsules, enteric-coated capsules, sustained-release capsules, controlled-release capsules, and the like.

[0034] It is to be understood that the oral liquid preparations described in the embodiments of the present invention include but are not limited to oral suspensions, oral emulsions, syrups, oral liquids, oral emulsions, emulsions, colloidal solutions, mixtures, dews, drops, suspension drops, etc.

[0035] It is to be understood that the oral granules described in the embodiments of the present invention include but are not limited to enteric-coated granules, sustained-release granules, fine granules, teas, suspension granules, effervescent granules, and the like.

[0036] It is to be understood that the oral powders described in the embodiments of the present invention include but are not limited to medicinal powders, powders, dry suspensions, etc.

[0037] It can be understood that the injection dosage forms described in the embodiments of the present invention include but are not limited to injection solutions, injection solutions, injection solutions for intravenous drip, injection suspensions, sterile powders for injection, intravenous injections, water injections, injection emulsions, powder injections, injections, sterile powder injections, freeze-dried powder injections, etc.

[0038] The beneficial effects of the present invention are:

[0039] The present invention verifies that glipizide can alleviate CCl4-induced liver fibrosis in mice, and verifies the therapeutic effect of glipizide on liver fibrosis by detecting the expression of Collagen I and α-SMA through hematoxylin-eosin staining (H&E staining), Sirius red staining, and immunohistochemical detection. It is found that the expression of collagen and the expression of Collagen I and α-SMA in the glipizide treatment group are significantly lower than those in the DMSO control group, indicating that glipizide significantly alleviates CCl4-induced liver fibrosis in mice. Therefore, glipizide can be used as a drug with development prospects for preventing and treating liver fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] The present invention will be further described below with reference to the accompanying drawings and embodiments, wherein:

[0041] Figure 1 These are the results of glipizide treatment of liver fibrosis in mice in an embodiment of the present invention, wherein Figure A is H&E staining of mouse liver tissue; Figure B is Sirius red staining of mouse liver tissue; Figure C is immunohistochemical detection of Collagen I expression; Figure D is immunohistochemical detection of α-SMA expression; Figure E is a quantitative bar graph of Sirius red staining positive area of ​​mouse liver tissue; Figure F is a quantitative bar graph of Collagen I expression detected by immunohistochemical detection; Figure G is a quantitative bar graph of α-SMA expression detected by immunohistochemical detection; * represents P<0.05. DETAILED DESCRIPTION

[0042] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0043] Example

[0044] 1. Construction and treatment of liver fibrosis model

[0045] Thirty-four 6-week-old male C57BL / 6J mice were randomly divided into 3 groups, namely blank control group (n=10), model group (injected with carbon tetrachloride CCl4 alone, n=12), and glipizide treatment group (n=12). The model group and glipizide treatment group were induced to liver fibrosis by intraperitoneal injection of CCl4 for 6 weeks. CCl4 was diluted with olive oil (Olive oil) at a ratio of 1:4, and 2 mL / kg was injected each time, twice a week. The blank control group was intraperitoneally injected with olive oil, 2 mL / kg, twice a week. At the same time, in the glipizide treatment group, mice were treated with glipizide (5 mg / kg) after each injection of CCl4. The blank control group and model group were intraperitoneally injected with DMSO instead of glipizide, twice a week, for a total of 6 weeks.

[0046] II. Obtaining Mouse Liver and Preparing Tissue Sections

[0047] 48 h after the last injection of CCl4, the mice were killed by cervical dislocation, and the livers were removed and prepared into paraffin sections.

[0048] 1. Fixation: Fix with 4% paraformaldehyde for 24 hours.

[0049] 2. Dehydration: Dehydrate the fixed tissue using gradient concentrations of alcohol, and soak it in 70%, 80%, 90%, 95% ethanol, anhydrous ethanol I and anhydrous ethanol II in sequence. Soak it in 70% to 95% ethanol for 30 minutes, and soak it in anhydrous ethanol I and anhydrous ethanol II for 1 hour.

[0050] 3. Transparency: Soak in xylene I for 1 hour and in xylene II for 1 hour.

[0051] 4. Wax immersion: After the tissue has become transparent, place it in low-melting-point paraffin for 1 hour and high-melting-point paraffin for 1 hour.

[0052] 5. Embedding: Melt the high melting point wax in an automatic embedding machine in advance and keep it in a molten state. Adjust the wax-soaked tissue to the state required for slicing and put it into the embedding box. Pour in the high melting point wax and place it on ice or at room temperature to wait for it to cool and solidify.

[0053] 6. Sectioning: Set the water temperature of the slide spreading pool to 42°C, the temperature of the slice baking area and the slice drying area to 65°C, and pre-cool the wax block in the refrigerator. After trimming to the required cross-section, adjust the slice thickness to 3μm and start slicing. Put the obtained slices into the slide spreading pool to remove wrinkles. After the slice is spread, use a slide pre-coated with APES to pick up the tissue, place it in the slice baking area or the slice drying area for 2 hours, and then store it at 4°C.

[0054] 3. Hematoxylin-eosin (HE) staining

[0055] 1. Dewaxing: Place the prepared paraffin sections in a 65°C oven for 10 to 20 minutes, then place the sections in xylene I (25 minutes) - xylene II (20 minutes) - anhydrous ethanol I (20 minutes) - anhydrous ethanol II (15 minutes) - 95% ethanol (10 minutes) - 80% ethanol (5 minutes) - 70% ethanol (5 minutes) for dewaxing.

[0056] 2. Staining: After dewaxing, soak the slices in a hematoxylin staining jar for 1.5min to 2min, then run water to blue for 30min to 45min, then soak the slices in an eosin staining jar for 10s. After that, wash off the excess staining solution with running water.

[0057] 3. Dehydration, transparency, and sealing: After staining, place the sections in 80% ethanol (10s)-90% ethanol (10s)-95% ethanol (10s)-anhydrous ethanol I (10s)-anhydrous ethanol II (10s)-xylene I (10s)-xylene II (10s) for dehydration and transparency, then dry in a ventilation window and seal with neutral gum.

[0058] The results are as follows Figure 1 As shown in Figure A, hepatocyte degeneration and hyperplasia of fibrous connective tissue in the portal area and interlobular areas can be seen in the Glipizide treatment group and the model group (DMSO+CCl4) in Figure A. Moreover, the degree of fibrous connective tissue hyperplasia in the glipizide treatment group was significantly lighter than that in the model group (DMSO+CCl4), indicating that glipizide inhibited the formation of liver fibrosis.

[0059] 4. Sirius Red Staining

[0060] 1. Dewaxing: Place the prepared paraffin sections in a 65°C oven for 10 to 20 minutes, then place the sections in xylene I (25 minutes) - xylene II (25 minutes - anhydrous ethanol I (20 minutes - anhydrous ethanol II (15 minutes) - 95% ethanol (10 minutes) - 80% ethanol (5 minutes) - 70% ethanol (5 minutes) for dewaxing.

[0061] 2. Soak in distilled water for 5 minutes to remove excess ethanol.

[0062] 3. Stain with Sirius red solution for 15 minutes in the dark, then decolorize by soaking in glacial acetic acid for 2 seconds.

[0063] 4. Dehydration: Place the stained sections in 75% ethanol (10s) - 85% ethanol (10s) - 95% ethanol (10s) - anhydrous ethanol (10s) - xylene I (10s) - xylene II (10s) for dehydration.

[0064] 5. Sealing: Place in a fume hood to air dry and seal with neutral gum.

[0065] The results are as follows Figure 1 As shown, from Figure 1 As can be seen from Figures B and E, the Sirius red staining-positive area in the Glipizide treatment group was smaller than that in the model group (DMSO+CCl4), indicating that the number of collagen fibers in the Glipizide treatment group was significantly less than that in the DMSO treatment group, indicating that Glipizide alleviated CCl4-induced liver fibrosis.

[0066] 5. Immunohistochemistry (IHC) detection of the expression of Collagen I and α-SMA

[0067] 1. Dewaxing: Place the prepared paraffin sections in a 65°C oven for 10-20 minutes, then place the sections in xylene I (25 minutes) - xylene II (25 minutes) - anhydrous ethanol I (20 minutes) - anhydrous ethanol II (15 minutes) - 95% ethanol (10 minutes) - 80% ethanol (5 minutes) - 70% ethanol (5 minutes) for dewaxing. After dewaxing, place the sections in 0.01M PBS and wash them on a shaker for three times, 5 minutes each time.

[0068] 2. Antigen repair: Place the tissue sections in a citric acid buffer solution and repair them under high temperature and high pressure for 14 minutes. After cooling naturally to room temperature, wash them three times with 0.01M PBS, each time for 5 minutes.

[0069] 3. Eliminate endogenous peroxidase activity: Place tissue slices in 3% H2O2-methanol solution, preheat for 30 minutes, and place at 37°C for 30 minutes. Remove slices from 3% H2O2-methanol solution and wash three times with 0.01M PBS, 5 minutes each time.

[0070] 4. Blocking: Wipe off the solution around the tissue on the tissue section, add 10% BSA to cover the tissue, place the tissue section in a humidified box, and then place the humidified box in a 37°C oven to block for 1 hour.

[0071] 5. Primary antibody incubation: Use a pipette to directly aspirate the 10% BSA, add the pre-configured primary antibody and place in a 4°C refrigerator overnight.

[0072] 6. Secondary antibody incubation: The next day, place the tissue sections and the wet box at room temperature for 20 minutes, then wash three times with 0.01M PBS, 5 minutes each time. Wipe the moisture around the tissue, add the prepared secondary antibody to the tissue, place it in a wet box, and incubate it in a 37°C oven for 1 hour.

[0073] 7. DAB color development, hematoxylin counterstaining: Take out the tissue slices from the wet box and wash them three times with 0.01M PBS, 5 minutes each time. Wipe the moisture around the tissue, add DAB Substrate Kit solution (prepared before use) to the tissue, let it stand at room temperature for about 1 minute, and place it in water to stop the reaction. Stain with hematoxylin for 10 seconds, wash off the stain with running water, and be careful not to let the water wash away the tissue.

[0074] 8. Dehydration and sealing: After staining, place the sections in 80% ethanol (10s)-90% ethanol (10s)-95% ethanol (10s)-anhydrous ethanol I (10s)-anhydrous ethanol II (10s)-xylene I (10s)-xylene II (10s) in sequence for dehydration and transparency, then dry in a ventilation window and seal with neutral gum.

[0075] The results are as follows Figure 1 As shown, from Figure 1 As shown in Figures C and F, the expression of Collagen Ⅰ in the Glipizide treatment group was lower than that in the liver fibrosis model group (DMSO+CCl4). Figure 1 As can be seen from Figures D and G, the expression level of α-SMA in the Glipizide treatment group was significantly lower than that in the liver fibrosis model group (DMSO+CCl4), indicating that Glipizide significantly inhibited CCl4-induced liver fibrosis.

[0076] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. Use of glipizide in preparing a medicament for treating liver fibrosis, characterized in that: The glipizide inhibits the expression level of Collagen I and / or α-SMA, and the liver fibrosis is caused by at least one of viral hepatitis, alcoholic liver injury and autoimmune liver disease.

2. The use according to claim 1, characterized in that: The medicine also includes pharmaceutically acceptable excipients.

3. The use according to claim 2, characterized in that: The dosage form of the drug is an oral dosage form or an injection dosage form.

4. The use according to claim 3, characterized in that: The oral dosage form is tablet, capsule, oral liquid, granule or powder.